Viatris (VTRS) Cost of Revenue (2020 - 2026)
Viatris (VTRS) recorded quarterly Cost of Revenue of $2.4 billion in Q1 2026, down 7.67% quarter-over-quarter from $2.6 billion in Q4 2025, and up 12.74% on a YoY basis from $2.1 billion in Q1 2025.
Viatris (VTRS) Cost of Revenue (2020 - 2026) Analysis & Trends
Viatris' Cost of Revenue history runs 7 years deep, the most recent figure standing at $2.4 billion for Q1 2026.
- In Q1 2026, Cost of Revenue rose 12.74% year-over-year to $2.4 billion; the TTM figure through Mar 2026 stood at $9.6 billion (up 5.57% YoY), while the FY2025 annual figure was $9.3 billion, up 1.87% from the prior year.
- Cost of Revenue was $2.4 billion for Q1 2026 at Viatris, down from $2.6 billion in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $2.6 billion in Q4 2022 to a low of $2.1 billion in Q1 2025.
- Historically, Cost of Revenue has averaged $2.3 billion across 5 years, with a median of $2.3 billion in 2024.
- The sharpest annual moves came in 2022 and 2026: Cost of Revenue fell 26.72% in 2022, then gained 12.74% in 2026.
- A 5-year view of Cost of Revenue shows it stood at $2.6 billion in 2022, then decreased by 13.88% to $2.2 billion in 2023, then gained by 3.23% to $2.3 billion in 2024, then grew by 10.49% to $2.6 billion in 2025, then declined by 7.67% to $2.4 billion in 2026.
- The last three Cost of Revenue figures came in at $2.4 billion (Q1 2026), $2.6 billion (Q4 2025), and $2.4 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 696.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 641.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 133.40 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 34.44 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 13.80 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 586.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | 155.56 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 52.68 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | 222.00 Mn |
| 10 | Viatris | - | - | 1.16 Bn | 2.36 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.36 Bn |
| Mar 31, 2026 | 2.36 Bn |
| Dec 31, 2025 | 2.56 Bn |
| Dec 31, 2025 | 2.56 Bn |
| Sep 30, 2025 | 2.39 Bn |
| Sep 30, 2025 | 2.39 Bn |
| Jun 30, 2025 | 2.25 Bn |
| Jun 30, 2025 | 2.25 Bn |
| Mar 31, 2025 | 2.09 Bn |
| Mar 31, 2025 | 2.09 Bn |
| Dec 31, 2024 | 2.31 Bn |
| Dec 31, 2024 | 2.31 Bn |
| Sep 30, 2024 | 2.29 Bn |
| Sep 30, 2024 | 2.29 Bn |
| Jun 30, 2024 | 2.35 Bn |
| Jun 30, 2024 | 2.35 Bn |
| Mar 31, 2024 | 2.16 Bn |
| Mar 31, 2024 | 2.16 Bn |
| Dec 31, 2023 | 2.24 Bn |
| Dec 31, 2023 | 2.24 Bn |